Drugs and medical devices authorized, April 1 to June 30, 2026

From April 1 to June 30, 2026, Health Canada approved 15 new drug submissions (8 pharmaceuticals, 7 biologics) and 481 new medical devices, including 22 Class IV medical devices, which present the greatest potential risk. During this period, Health Canada also approved 31 generic drugs and 10 biosimilar drugs.

July 2026

From April 1 to June 30, 2026, Health Canada approved 15 new drug submissions (8 pharmaceuticals, 7 biologics) and 481 new medical devices, including 22 Class IV medical devices, which present the greatest potential risk. During this period, Health Canada also approved 31 generic drugs and 10 biosimilar drugs.

For more information on these and other drug and medical device approvals, consult:

• The Drug Product Database, which contains product-specific information on drugs that have been approved for use in Canada such as their availability and product monograph.
• The Medical Devices Active Licence Listing (MDALL) database, which contains the complete list of all medical devices that have been authorized for sale in Canada.

• Medical devices in Canada are classified from Class I to Class IV based on the level of risk they pose. Class IV devices represent the highest-risk category and are subject to a rigorous pre-market review by Health Canada to ensure that they meet safety, effectiveness and quality requirements before they can be sold in Canada.

• Regulatory Decision Summaries and Summary Basis of Decisions, which explain why Health Canada authorized certain health products.